GALECTIN THERAPEUTICS INC. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
GALECTIN THERAPEUTICS INC. (GALT) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $2.45 per share as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2026-03-31
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $2.45.
- 2024-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $2.45.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $2.79.
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $3.35.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $2.45 10-K · filed 2026-03-31 |
| 2024-12-31 | $2.45 10-K · filed 2025-03-31 |
| 2023-12-31 | $2.79 10-K · filed 2024-03-29 |
| 2022-12-31 | $3.35 10-K · filed 2023-03-30 |
| 2021-12-31 | $4.09 10-K · filed 2022-03-31 |
| 2020-12-31 | $4.68 10-K · filed 2021-03-31 |
| 2019-12-31 | $4.90 10-K · filed 2020-03-16 |
| 2018-12-31 | $4.68 10-K · filed 2019-03-06 |
| 2017-12-31 | $4.37 10-K · filed 2018-03-29 |
| 2016-12-31 | $5.44 10-K · filed 2017-03-28 |
| 2015-12-31 | $5.68 10-K · filed 2016-03-15 |
| 2014-12-31 | $5.24 10-K · filed 2015-03-18 |
| 2013-12-31 | $4.43 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |